KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Acadia Pharmaceuticals (ACAD) over the last 13 years, with Q3 2025 value amounting to $388000.0.

  • Acadia Pharmaceuticals' Capital Expenditures rose 45428.57% to $388000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $911000.0, marking a year-over-year increase of 120142.86%. This contributed to the annual value of $523000.0 for FY2024, which is 94600.0% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Capital Expenditures stood at $388000.0 for Q3 2025, which was up 45428.57% from $453000.0 recorded in Q4 2024.
  • Acadia Pharmaceuticals' 5-year Capital Expenditures high stood at $1.1 million for Q1 2021, and its period low was $1000.0 during Q4 2021.
  • Over the past 3 years, Acadia Pharmaceuticals' median Capital Expenditures value was $229000.0 (recorded in 2024), while the average stood at $338833.3.
  • Its Capital Expenditures has fluctuated over the past 5 years, first crashed by 9995.0% in 2021, then skyrocketed by 45428.57% in 2025.
  • Quarter analysis of 3 years shows Acadia Pharmaceuticals' Capital Expenditures stood at $1000.0 in 2021, then soared by 45200.0% to $453000.0 in 2024, then decreased by 14.35% to $388000.0 in 2025.
  • Its Capital Expenditures stands at $388000.0 for Q3 2025, versus $453000.0 for Q4 2024 and $70000.0 for Q3 2024.